Dianthus Therapeutics

DNTH · NASDAQ

$78.75+$4.21 (+5.65%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $74.54

DNTH analyst rating

BuyConsensus of 14 analysts over the last 12 months. 100% rate it a buy.

Strong buy1
Buy13
Hold0
Underperform0
Sell0

12-month price target · 16 analysts

Average $142.14 (+80.5% upside)

Low: $123.22
Now: $78.75
High: $210.00

Upgrades and downgrades

The latest rating actions, newest first

DNTH analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 15, 2026	Maintains	Buy	$158.00	43%
JP Morgan	Sep 11, 2026	Initiates	Overweight	$135.00	40%
Citigroup	Sep 4, 2026	Initiates	Buy	$156.00	36%
Truist Securities	Aug 6, 2026	Maintains	Buy	$110.00 → $128.00	36%
HC Wainwright & Co.	Aug 6, 2026	Maintains	Buy	$130.00 → $158.00	43%
Wedbush	Aug 5, 2026	Maintains	Outperform	$105.00 → $122.00	40%
Evercore ISI Group	Aug 3, 2026	Maintains	Outperform	$120.00 → $134.00	42%
Wedbush	May 6, 2026	Maintains	Outperform	$103.00 → $105.00	40%
Wolfe Research	Apr 9, 2026	Initiates	Outperform	$98.00	47%
Wells Fargo	Mar 19, 2026	Initiates	Overweight	$135.00	25%

The case for and against

Updated Oct 14, 2026

Bull case

Dianthus Therapeutics is attractive fundamentally because its lead asset class is aimed at validated autoimmune pathways, while the internally developed DNTH312 should improve economics versus the in-licensed DNTH212 and extend franchise IP protection to at least 2047, versus at least 2043 for claseprubart. Management’s strategy also benefits from an experienced clinical team and evidence that DNTH312 produced comparable in vitro potency to claseprubart, plus durable NHP pharmacology with a roughly 22-day half-life and meaningful Ig reductions. With current cash of $1.2B providing runway beyond pivotal claseprubart readouts and key programs such as Phase 2 MMN now tracking to 4Q26, the company appears well positioned to fund multiple shots on goal.

Bear case

Dianthus Therapeutics is viewed negatively because its investment case still depends on a single clinical-stage asset, Claseprubart, while regulatory risk remains elevated and approval may require additional or longer studies if accelerated pathways are not accepted. Although 1Q26 revenue was $0.5M and GAAP EPS of $(0.85) beat consensus, the business is still far from meaningful commercialization, and the company must keep funding development and future launch efforts. Even with $1.2B in cash and a runway into 2030 after the $719M secondary offering, competitive pressure, uncertain labeling, and the need to access capital markets underscore a fragile long-term fundamental outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.